These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 22686344)

  • 1. Accelerated in-vitro release testing methods for extended-release parenteral dosage forms.
    Shen J; Burgess DJ
    J Pharm Pharmacol; 2012 Jul; 64(7):986-96. PubMed ID: 22686344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-vitro dissolution methods for controlled release parenterals and their applicability to drug-eluting stent testing.
    Seidlitz A; Weitschies W
    J Pharm Pharmacol; 2012 Jul; 64(7):969-85. PubMed ID: 22686343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissolution testing of oral modified-release dosage forms.
    Garbacz G; Klein S
    J Pharm Pharmacol; 2012 Jul; 64(7):944-68. PubMed ID: 22686342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro-in vivo correlation for complex non-oral drug products: Where do we stand?
    Shen J; Burgess DJ
    J Control Release; 2015 Dec; 219():644-651. PubMed ID: 26419305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro - in vivo correlation: from theory to applications.
    Emami J
    J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biorelevant in-vitro performance testing of orally administered dosage forms.
    Reppas C; Vertzoni M
    J Pharm Pharmacol; 2012 Jul; 64(7):919-30. PubMed ID: 22686340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward Higher QA: From Parametric Release of Sterile Parenteral Products to PAT for Other Pharmaceutical Dosage Forms.
    Hock SC; Constance NX; Wah CL
    PDA J Pharm Sci Technol; 2012; 66(4):371-91. PubMed ID: 22767885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breakout session summary from AAPS/CRS joint workshop on critical variables in the in vitro and in vivo performance of parenteral sustained release products.
    Martinez MN; Rathbone MJ; Burgess D; Huynh M
    J Control Release; 2010 Feb; 142(1):2-7. PubMed ID: 19808069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profiling in vitro drug release from subcutaneous implants: a review of current status and potential implications on drug product development.
    Iyer SS; Barr WH; Karnes HT
    Biopharm Drug Dispos; 2006 May; 27(4):157-70. PubMed ID: 16416503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prolonged-release drug formulations for parenteral administration. Part l. Suspensions and oily solutions for injection].
    Płaczek M; Jacyna J; Sznitowska M
    Pol Merkur Lekarski; 2013 Dec; 35(210):391-6. PubMed ID: 24490472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biorelevant in vitro performance testing of orally administered dosage forms-workshop report.
    Reppas C; Friedel HD; Barker AR; Buhse LF; Cecil TL; Keitel S; Kraemer J; Morris JM; Shah VP; Stickelmeyer MP; Yomota C; Brown CK
    Pharm Res; 2014 Jul; 31(7):1867-76. PubMed ID: 24643933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. USP Apparatus 4: a Valuable In Vitro Tool to Enable Formulation Development of Long-Acting Parenteral (LAP) Nanosuspension Formulations of Poorly Water-Soluble Compounds.
    Forrest WP; Reuter KG; Shah V; Kazakevich I; Heslinga M; Dudhat S; Patel S; Neri C; Mao Y
    AAPS PharmSciTech; 2018 Jan; 19(1):413-424. PubMed ID: 28755052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating the feasibility of temperature-controlled accelerated drug release testing for an intravaginal ring.
    Externbrink A; Clark MR; Friend DR; Klein S
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):966-73. PubMed ID: 23791685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of In Vitro-In Vivo Correlation (IVIVC) to facilitate the development of polymer-based controlled release injectable formulation.
    Mitra A; Wu Y
    Recent Pat Drug Deliv Formul; 2010 Jun; 4(2):94-104. PubMed ID: 20214657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing dissolution testing methodologies for extended-release oral dosage forms with supersaturating properties. Case example: Solid dispersion matrix of indomethacin.
    Tajiri T; Morita S; Sakamoto R; Mimura H; Ozaki Y; Reppas C; Kitamura S
    Int J Pharm; 2015 Jul; 490(1-2):368-74. PubMed ID: 26022889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerated in vitro release testing method for naltrexone loaded PLGA microspheres.
    Andhariya JV; Choi S; Wang Y; Zou Y; Burgess DJ; Shen J
    Int J Pharm; 2017 Mar; 520(1-2):79-85. PubMed ID: 28153651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory aspects of modified release dosage forms: special cases of dissolution testing using the flow-through system.
    Möller H; Wirbitzki E
    Boll Chim Farm; 1993 Apr; 132(4):105-15. PubMed ID: 8333916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of in vitro release models in formulation development and quality control of parenteral depots.
    Larsen C; Larsen SW; Jensen H; Yaghmur A; Ostergaard J
    Expert Opin Drug Deliv; 2009 Dec; 6(12):1283-95. PubMed ID: 19941410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FIP/AAPS joint workshop report: dissolution/in vitro release testing of novel/special dosage forms.
    Brown CK; Friedel HD; Barker AR; Buhse LF; Keitel S; Cecil TL; Kraemer J; Morris JM; Reppas C; Stickelmeyer MP; Yomota C; Shah VP
    AAPS PharmSciTech; 2011 Jun; 12(2):782-94. PubMed ID: 21688063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Dissolution Medium pH and Simulated Gastrointestinal Contraction on Drug Release From Nifedipine Extended-Release Tablets.
    Gao Z; Ngo C; Ye W; Rodriguez JD; Keire D; Sun D; Wen H; Jiang W
    J Pharm Sci; 2019 Mar; 108(3):1189-1194. PubMed ID: 30343136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.